Modality
mRNA
MOA
VEGFi
Target
PLK4
Pathway
PI3K/AKT
NBHCC
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
Dec 2019
→ Jul 2026
Phase 2Current
NCT07632868
1,288 pts·NB
2019-12→2026-07·Terminated
1,288 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-013mo awayPh3 Readout· NB
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2/3
Termina…
Catalysts
Ph3 Readout
2026-07-01 · 3mo away
NB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07632868 | Phase 2/3 | NB | Terminated | 1288 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |